HC Wainwright Reaffirms “Buy” Rating for Kezar Life Sciences (NASDAQ:KZR)

HC Wainwright reissued their buy rating on shares of Kezar Life Sciences (NASDAQ:KZR) in a report issued on Tuesday morning, AnalystRatings.com reports. The brokerage currently has a $12.00 price target on the stock.

Several other equities analysts also recently issued reports on KZR. Wells Fargo & Company reissued a market perform rating and set a $18.00 price objective on shares of Kezar Life Sciences in a research note on Sunday, June 14th. Zacks Investment Research downgraded shares of Kezar Life Sciences from a buy rating to a hold rating in a research note on Friday, August 28th. BidaskClub downgraded shares of Kezar Life Sciences from a sell rating to a strong sell rating in a research note on Friday, June 5th. ValuEngine downgraded shares of Kezar Life Sciences from a strong-buy rating to a buy rating in a research note on Thursday, June 4th. Finally, Cowen reissued an outperform rating on shares of Kezar Life Sciences in a research note on Sunday, June 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Kezar Life Sciences currently has an average rating of Hold and an average target price of $11.83.

Shares of NASDAQ KZR opened at $4.53 on Tuesday. Kezar Life Sciences has a 12-month low of $2.18 and a 12-month high of $9.79. The company has a market capitalization of $209.54 million, a PE ratio of -3.02 and a beta of 0.14. The company has a debt-to-equity ratio of 0.03, a current ratio of 31.83 and a quick ratio of 31.83. The firm’s 50-day moving average is $4.75 and its two-hundred day moving average is $4.84.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.04. On average, analysts forecast that Kezar Life Sciences will post -0.93 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. Two Sigma Advisers LP raised its stake in Kezar Life Sciences by 56.5% during the second quarter. Two Sigma Advisers LP now owns 100,300 shares of the company’s stock worth $520,000 after purchasing an additional 36,200 shares during the period. Nuveen Asset Management LLC increased its position in shares of Kezar Life Sciences by 19.5% in the second quarter. Nuveen Asset Management LLC now owns 133,014 shares of the company’s stock worth $689,000 after acquiring an additional 21,732 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Kezar Life Sciences in the second quarter worth $118,000. Luminus Management LLC acquired a new stake in shares of Kezar Life Sciences in the second quarter worth $1,342,000. Finally, Bank of America Corp DE increased its position in shares of Kezar Life Sciences by 47.3% in the second quarter. Bank of America Corp DE now owns 26,684 shares of the company’s stock worth $138,000 after acquiring an additional 8,573 shares in the last quarter. 50.15% of the stock is currently owned by institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Further Reading: What do investors mean by earnings per share?

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.